#Japan #Tokyo #MicroRNA-4516 #EXORPHIA #MSC-EV

New Approaches to Lung Fibrosis Treatment

In an exciting development for pulmonary health, EXORPHIA Co., Ltd., headquartered in Tokyo, has collaborated with Juntendo University’s Department of Respiratory Medicine to investigate a promising new approach for treating lung fibrosis. Their research has identified the mechanisms through which MicroRNA-4516, abundant in their proprietary MSC-EV (mesenchymal stem cell-derived extracellular vesicles), inhibits the progression of this serious condition. The findings have been published in the prestigious journal Stem Cell Research & Therapy, which is highly regarded in the fields of stem cell and regenerative medicine.

Understanding Lung Fibrosis

Lung fibrosis represents a complex challenge in medical science. This progressive and often hard-to-treat condition leads to the stiffening of lung tissues, resulting in a significant reduction in respiratory function, and unfortunately, the prognosis for those affected is poor. Existing treatment options only marginally slow the progression of the disease, and no definitive cure currently exists. Therefore, the development of innovative therapeutic strategies to address lung fibrosis is urgently needed.

Research Findings

In this collaborative study, EXORPHIA took the lead on producing and characterizing the MSC-EVs and evaluating their efficacy in animal models. Meanwhile, Juntendo University focused on unraveling the mechanisms by which these nanoparticles exert their influence. The results have revealed that MicroRNA-4516 has a crucial role in modulating signaling pathways associated with fibrosis, effectively curbing the disease’s advancement.

Notably, the animal studies provided compelling evidence of the ability of MSC-EV containing MicroRNA-4516 to suppress lung fibrosis. These results lay a strong scientific foundation for the potential clinical application of this innovative therapy.

A Unique Production Method

The proprietary EV production method developed by EXORPHIA demonstrates higher reproducibility and stability compared to traditional manufacturing techniques. This method aligns with GMP (Good Manufacturing Practices) standards, anticipating its application in clinical settings. Furthermore, through quantitative and qualitative assessments of specific microRNAs within the EVs—such as MicroRNA-4516—EXORPHIA aims to achieve standardized EV drug development, setting a benchmark in the industry.

EXORPHIA's MSC-EVs are currently under a patent application (International Publication Number WO2024/242132) and have been confirmed to contain an abundance of MicroRNA-4516, emphasizing the company’s scientific edge in EV-based drug development.

Moving Forward

As a result of these promising findings, EXORPHIA is accelerating the development of EV-based therapeutics targeting inflammatory and fibrotic diseases, starting with lung fibrosis. The company is also committed to expanding applications through collaborations with academic institutions and pharmaceutical companies, ensuring responsible commercialization of its innovations.

Conclusion

This promising research heralds new hope for patients suffering from lung fibrosis. With the backing of rigorous scientific investigations and a commitment to innovation, EXORPHIA is paving the way towards effective therapies in a previously challenging therapeutic landscape. The publication can be found in Stem Cell Research & Therapy and highlights a significant step forward in regenerative medicine.

For further information, visit EXORPHIA's website or contact their public relations team via email at [email protected].